nodes	percent_of_prediction	percent_of_DWPC	metapath
Meropenem—Urticaria—Teniposide—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Meropenem—Glossitis—Methotrexate—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Meropenem—Haemorrhage—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Meropenem—Abdominal pain—Teniposide—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Meropenem—Body temperature increased—Teniposide—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Meropenem—Erythema—Bleomycin—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Meropenem—Paraesthesia—Fludarabine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Meropenem—Hallucination—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Meropenem—Sweating—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Meropenem—Dyspnoea—Fludarabine—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Meropenem—Oedema peripheral—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Meropenem—Dyspepsia—Fludarabine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Meropenem—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Meropenem—Decreased appetite—Fludarabine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Meropenem—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Meropenem—Inflammation—Methotrexate—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Meropenem—Hallucination—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Meropenem—Pain—Fludarabine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Meropenem—Constipation—Fludarabine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Meropenem—Bradycardia—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Meropenem—Respiratory failure—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Meropenem—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Meropenem—Hypersensitivity—Teniposide—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Meropenem—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Meropenem—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Meropenem—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Meropenem—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Meropenem—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Meropenem—Anaemia—Bleomycin—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Meropenem—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Meropenem—Asthenia—Teniposide—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Meropenem—Melaena—Methotrexate—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Meropenem—Malaise—Bleomycin—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Meropenem—Pruritus—Teniposide—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Meropenem—Leukopenia—Bleomycin—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Meropenem—Body temperature increased—Fludarabine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Meropenem—Vaginal infection—Methotrexate—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Meropenem—Erythema—Carmustine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Meropenem—Cough—Bleomycin—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Meropenem—Diarrhoea—Teniposide—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Meropenem—Chest pain—Bleomycin—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Meropenem—Back pain—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Meropenem—Chills—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Meropenem—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Meropenem—Confusional state—Bleomycin—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Meropenem—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Meropenem—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Meropenem—Oedema—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Meropenem—Erythema—Mitoxantrone—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Meropenem—Infection—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Meropenem—Anaemia—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Meropenem—Back pain—Vincristine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Meropenem—Vomiting—Teniposide—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Meropenem—Sepsis—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Meropenem—Agitation—Carmustine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Meropenem—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Meropenem—Asthenia—Fludarabine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Meropenem—Rash—Teniposide—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Meropenem—Dermatitis—Teniposide—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Meropenem—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Meropenem—Headache—Teniposide—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Meropenem—Pruritus—Fludarabine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Meropenem—Back pain—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Meropenem—Leukopenia—Carmustine—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Meropenem—Anorexia—Bleomycin—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Meropenem—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Meropenem—Anaemia—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Meropenem—Agitation—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Meropenem—Hypotension—Bleomycin—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Meropenem—Diarrhoea—Fludarabine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Meropenem—Hypertension—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Meropenem—Nausea—Teniposide—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Meropenem—Anaemia—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Meropenem—Hepatic failure—Methotrexate—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Meropenem—Leukopenia—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Meropenem—Chest pain—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Meropenem—Anxiety—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Meropenem—Paraesthesia—Bleomycin—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Meropenem—Malaise—Mitoxantrone—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Meropenem—Dyspnoea—Bleomycin—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Meropenem—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Meropenem—Hypertension—Vincristine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Meropenem—Confusional state—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Meropenem—Oedema—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Meropenem—Decreased appetite—Bleomycin—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Meropenem—Cough—Mitoxantrone—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Meropenem—Infection—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Meropenem—Vomiting—Fludarabine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Meropenem—Rash—Fludarabine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Meropenem—Dermatitis—Fludarabine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Meropenem—Hypertension—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Meropenem—Pain—Bleomycin—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Meropenem—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Meropenem—Headache—Fludarabine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Meropenem—Tachycardia—Carmustine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Meropenem—Chest pain—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Meropenem—Anxiety—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Meropenem—Oedema—Vincristine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Meropenem—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Meropenem—Anorexia—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Meropenem—Infection—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Meropenem—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Meropenem—Confusional state—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Meropenem—Nervous system disorder—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Meropenem—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Meropenem—Hypotension—Carmustine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Meropenem—Oedema—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Meropenem—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Meropenem—Nausea—Fludarabine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Meropenem—Infection—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Meropenem—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Meropenem—Shock—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Meropenem—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Meropenem—Urticaria—Bleomycin—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Meropenem—Anorexia—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Meropenem—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Meropenem—Body temperature increased—Bleomycin—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Meropenem—Insomnia—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Meropenem—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Meropenem—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Meropenem—Paraesthesia—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Meropenem—Hypotension—Vincristine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Meropenem—Dyspnoea—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Meropenem—Somnolence—Carmustine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Meropenem—Anorexia—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Meropenem—Decreased appetite—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Meropenem—Hypotension—Mitoxantrone—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Meropenem—Insomnia—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Meropenem—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Meropenem—Paraesthesia—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Meropenem—Pain—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Meropenem—Constipation—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Meropenem—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Meropenem—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Meropenem—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Meropenem—Decreased appetite—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Meropenem—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Meropenem—Somnolence—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Meropenem—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Meropenem—Feeling abnormal—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Meropenem—Asthenia—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Meropenem—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Meropenem—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Meropenem—Pain—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Meropenem—Constipation—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Meropenem—Asthma—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Meropenem—Pruritus—Bleomycin—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Meropenem—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Meropenem—Eosinophilia—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Meropenem—Pain—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Meropenem—Constipation—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Meropenem—Abdominal pain—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Meropenem—Body temperature increased—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Meropenem—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Meropenem—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Meropenem—Neutropenia—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Meropenem—Dysuria—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Meropenem—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Meropenem—Abdominal pain—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Meropenem—Body temperature increased—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Meropenem—Urticaria—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Meropenem—Hypersensitivity—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Meropenem—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Meropenem—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Meropenem—Pneumonia—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Meropenem—Vomiting—Bleomycin—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Meropenem—Infestation NOS—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Meropenem—Infestation—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Meropenem—Rash—Bleomycin—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Meropenem—Dermatitis—Bleomycin—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Meropenem—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Meropenem—Asthenia—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Meropenem—Renal failure—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Meropenem—Hypersensitivity—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Meropenem—Sweating—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Meropenem—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Meropenem—Epistaxis—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Meropenem—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Meropenem—Asthenia—Vincristine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Meropenem—Diarrhoea—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Meropenem—Nausea—Bleomycin—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Meropenem—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Meropenem—Asthenia—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Meropenem—Dizziness—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Meropenem—Haemoglobin—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Meropenem—Diarrhoea—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Meropenem—Hepatitis—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Meropenem—Haemorrhage—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Meropenem—Pharyngitis—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Meropenem—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Meropenem—Vomiting—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Meropenem—Dizziness—Vincristine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Meropenem—Rash—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Meropenem—Dermatitis—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Meropenem—Headache—Carmustine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Meropenem—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Meropenem—Vomiting—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Meropenem—Rash—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Meropenem—Dermatitis—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Meropenem—Headache—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Meropenem—Nausea—Carmustine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Meropenem—Vomiting—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Meropenem—Immune system disorder—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Meropenem—Rash—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Meropenem—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Meropenem—Chills—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Meropenem—Headache—Mitoxantrone—lymphatic system cancer	0.001	0.001	CcSEcCtD
Meropenem—Erythema—Methotrexate—lymphatic system cancer	0.000978	0.000978	CcSEcCtD
Meropenem—Nausea—Vincristine—lymphatic system cancer	0.000977	0.000977	CcSEcCtD
Meropenem—Dysgeusia—Methotrexate—lymphatic system cancer	0.000958	0.000958	CcSEcCtD
Meropenem—Nausea—Mitoxantrone—lymphatic system cancer	0.000952	0.000952	CcSEcCtD
Meropenem—Back pain—Methotrexate—lymphatic system cancer	0.000946	0.000946	CcSEcCtD
Meropenem—Anaemia—Methotrexate—lymphatic system cancer	0.000904	0.000904	CcSEcCtD
Meropenem—Malaise—Methotrexate—lymphatic system cancer	0.000882	0.000882	CcSEcCtD
Meropenem—Leukopenia—Methotrexate—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Meropenem—Cough—Methotrexate—lymphatic system cancer	0.000854	0.000854	CcSEcCtD
Meropenem—Chest pain—Methotrexate—lymphatic system cancer	0.000833	0.000833	CcSEcCtD
Meropenem—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000827	0.000827	CcSEcCtD
Meropenem—Confusional state—Methotrexate—lymphatic system cancer	0.000805	0.000805	CcSEcCtD
Meropenem—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000798	0.000798	CcSEcCtD
Meropenem—Infection—Methotrexate—lymphatic system cancer	0.000793	0.000793	CcSEcCtD
Meropenem—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000783	0.000783	CcSEcCtD
Meropenem—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000782	0.000782	CcSEcCtD
Meropenem—Skin disorder—Methotrexate—lymphatic system cancer	0.000776	0.000776	CcSEcCtD
Meropenem—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000772	0.000772	CcSEcCtD
Meropenem—Anorexia—Methotrexate—lymphatic system cancer	0.000761	0.000761	CcSEcCtD
Meropenem—Hypotension—Methotrexate—lymphatic system cancer	0.000746	0.000746	CcSEcCtD
Meropenem—Insomnia—Methotrexate—lymphatic system cancer	0.000722	0.000722	CcSEcCtD
Meropenem—Paraesthesia—Methotrexate—lymphatic system cancer	0.000717	0.000717	CcSEcCtD
Meropenem—Dyspnoea—Methotrexate—lymphatic system cancer	0.000712	0.000712	CcSEcCtD
Meropenem—Somnolence—Methotrexate—lymphatic system cancer	0.00071	0.00071	CcSEcCtD
Meropenem—Dyspepsia—Methotrexate—lymphatic system cancer	0.000703	0.000703	CcSEcCtD
Meropenem—Decreased appetite—Methotrexate—lymphatic system cancer	0.000694	0.000694	CcSEcCtD
Meropenem—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000689	0.000689	CcSEcCtD
Meropenem—Pain—Methotrexate—lymphatic system cancer	0.000683	0.000683	CcSEcCtD
Meropenem—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000658	0.000658	CcSEcCtD
Meropenem—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000653	0.000653	CcSEcCtD
Meropenem—Urticaria—Methotrexate—lymphatic system cancer	0.000634	0.000634	CcSEcCtD
Meropenem—Body temperature increased—Methotrexate—lymphatic system cancer	0.000631	0.000631	CcSEcCtD
Meropenem—Abdominal pain—Methotrexate—lymphatic system cancer	0.000631	0.000631	CcSEcCtD
Meropenem—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000588	0.000588	CcSEcCtD
Meropenem—Asthenia—Methotrexate—lymphatic system cancer	0.000573	0.000573	CcSEcCtD
Meropenem—Pruritus—Methotrexate—lymphatic system cancer	0.000565	0.000565	CcSEcCtD
Meropenem—Diarrhoea—Methotrexate—lymphatic system cancer	0.000546	0.000546	CcSEcCtD
Meropenem—Dizziness—Methotrexate—lymphatic system cancer	0.000528	0.000528	CcSEcCtD
Meropenem—Vomiting—Methotrexate—lymphatic system cancer	0.000508	0.000508	CcSEcCtD
Meropenem—Rash—Methotrexate—lymphatic system cancer	0.000503	0.000503	CcSEcCtD
Meropenem—Dermatitis—Methotrexate—lymphatic system cancer	0.000503	0.000503	CcSEcCtD
Meropenem—Headache—Methotrexate—lymphatic system cancer	0.0005	0.0005	CcSEcCtD
Meropenem—Nausea—Methotrexate—lymphatic system cancer	0.000474	0.000474	CcSEcCtD
